EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Subclinical Vascular Inflammation in Patients Receiving Pembrolizumab Detected by 18F-FDG PET/CT

Marcelino Mederos Liriano, Mohamed AlHajji, Maad Alhudairy, Sobha Kurian, Nour Daboul, Maria Hafez, Amber Sharma, Kenneth Wang, Omar Sabbagh, Yasmin Hamirani, James Mills, Brijesh Patel

Clinical Nuclear Medicine Open · 2025

DOI: 10.1097/nm9.0000000000000016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Nuclear Medicine Open, 2025. Verfasst von Marcelino Mederos Liriano und 11 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors have revolutionized the treatment of many tumors. Despite good clinical outcomes, unique immune-related adverse complications can occur with their use. Cardiac-related adverse events have been reported with pembrolizumab. However, data on the current trends of vascular inflammation in patients who received pembrolizumab are lacking. Patient and Methods: We chose the target-to-background ratio of the ascending aorta (TBR AA ), derived from 18 F-FDG tracer PET to capture changes in subclinical vascular inflammation after pembrolizumab administration. Our sample was drawn from a consecutive cohort of patients, with 70 out of 786 patients in our population pool meeting the inclusion criteria.

Results

The median TBR AA before and after pembrolizumab therapy was 1.30 (interquartile range: 1.20–1.41) and 1.36 (interquartile range: 1.25–1.49), respectively. The difference between pre to post-pembrolizumab administration was statistically significant, with a P value of 0.02. When adjusted for risk factors and number of doses to predict change from pre to post-pembrolizumab administration TBRs, none of the variables was associated with the changes seen in TBR post-pembrolizumab therapy.

Conclusion

Our analysis showed that there is a statistically significant median increase in the TBR AA after pembrolizumab administration, revealing evidence of a modest increase in vascular inflammation in patients receiving the drug.

Zitieren

APA

Liriano, M. M., AlHajji, M., Alhudairy, M., Kurian, S., Daboul, N., Hafez, M., Sharma, A., Wang, K., Sabbagh, O., Hamirani, Y., Mills, J., & Patel, B. (2025). Subclinical Vascular Inflammation in Patients Receiving Pembrolizumab Detected by 18F-FDG PET/CT. Clinical Nuclear Medicine Open. https://doi.org/10.1097/nm9.0000000000000016

Vancouver

Liriano MM, AlHajji M, Alhudairy M, Kurian S, Daboul N, Hafez M, et al. Subclinical Vascular Inflammation in Patients Receiving Pembrolizumab Detected by 18F-FDG PET/CT. Clinical Nuclear Medicine Open. 2025. doi:10.1097/nm9.0000000000000016

BibTeX
@article{Liriano2025,
  author = {Liriano, Marcelino Mederos and AlHajji, Mohamed and Alhudairy, Maad and Kurian, Sobha and Daboul, Nour and Hafez, Maria and Sharma, Amber and Wang, Kenneth and Sabbagh, Omar and Hamirani, Yasmin and Mills, James and Patel, Brijesh},
  title = {Subclinical Vascular Inflammation in Patients Receiving Pembrolizumab Detected by 18F-FDG PET/CT},
  journal = {Clinical Nuclear Medicine Open},
  year = {2025},
  doi = {10.1097/nm9.0000000000000016}
}
Kostenlos starten →